Health economics in decision making for influenza management

International Congress Series

Volumn 1219, Issue C, 2001, Pages 81-85

  Scuffham, Paul A ^a   Posnett, John W ^a   West, Peter A ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Antiviral prophylaxis; Antiviral treatment; Cost effectiveness; Health policy; Vaccine

Indexed keywords

EID: 0242376096     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00329-6     Document Type: Article

References (8)

1. Fedson, D.S., Evaluating the impact of influenza vaccination a North American perspective. PharmacoEconomics 9:Suppl. 3 (1996), 54–61.
2. Nichol, K.L., Goodman, M., The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65–74 years. PharmacoEconomics 16:Suppl. 1 (1999), 63–71.
3. Kastrissios, H., Blaschke, T.F., Medication compliance as a feature in drug development. Annu. Rev. Pharmacol. Toxicol. 37 (1997), 451–475.
4. Myint, M.W.W., Kng, C., Wong, C.P., Mak, C., Use of amantadine as prophylaxis for influenza A in a subvented care and attention home in Hong Kong. Hong Kong Pract. 20:10 (1998), 534–543.
5. Gross, P.A., Hermogenes, A.W., Sacks, H.S., Lau, J., Levandowski, R.A., The efficacy of influenza vaccine in elderly persons. Ann. Intern. Med. 123:7 (1995), 518–527.
6. Demicheli, V., Jefferson, T., Rivetti, D., Deeks, J., Prevention and early treatment of influenza in healthy adults. Vaccine 18:11–12 (2000), 957–1030.
7. NICE. Fast Track Appraisal of Zanamivir (Relenza): Summary of Evidence, 2000, National Institute for Clinical Excellence, London.
8. FDA, Important Drug Warning: Zanamivir for Inhalation. U.S. Food and Drug Administration, Washington.